UNSPSC 51282510: Cefazedone

This classification denotes a cephalosporin antibiotic with the molecular formula C18H15Cl2N5O5S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7Y86X0D799, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((3,5-dichloro-4-oxo-1(4h)-pyridinyl)acetyl)amino)-3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-, (6r-trans)- but generally known as cefazedone, which bears US NIH Compound Identifier 71736.

UNSPSC 51282510 Cefazedone is a Commodity code that in recent state and local procurement activity spans a broader range of pharmaceutical and medical supply categories than the code name alone suggests. The recent opportunities solicited under this code include naloxone and drug deactivation systems, medical and first aid supplies for emergency response, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing, and exploratory market intelligence on direct-to-manufacturer prescription programs. Issuing bodies include county health departments (Seminole County, Florida), municipal fire services (City of Tampa), state HHS commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across multiple states including Oregon). The Tampa procurement is sheltered exclusively for certified Small Local Business Enterprises with a 5 percent bid discount up to $10,000.

Activity appears concentrated in Florida, Texas, and Minnesota. Seminole County posted an IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: date discrepancy in source); the City of Tampa issued an IFB for 169 line items of medical and emergency response supplies estimated at $700,000 with a response deadline of March 13, 2026; the Texas Health and Human Services Commission released an RFI on direct-to-manufacturer prescription programs with a response deadline of April 3, 2026; and the Minnesota Department of Administration's Office of State Procurement, administering MMCAP, posted an RFP for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. The MMCAP RFP requires NDC-specific pricing from manufacturers distributed through three authorized wholesalers with contract effectiveness targeted for July 1, 2026, a two-year initial term, and a required 3 percent administrative fee on all contract purchases.